|
Hemato-oncology
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
Jung Sun Kim, Tae Min Kim, Myoung Joo Kang, Sung Ae Koh, Hyunkyung Park, Seung-Hyun Nam, Jae Joon Han, Gyeong-Won Lee, Young Jin Yuh, Hee Jeong Lee, Jung Hye Choi
Korean J Intern Med. 2023;38(5):747-757. Published online June 26, 2023
Background/Aims: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL.
Methods: A t..
|
|
|
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2021;36(4):975-984. Published online April 6, 2021
Background/Aims: Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer.
Methods: This study included patients with non-small cell..
|
|
|
Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma
Hyerim Ha, Bhumsuk Keam, Chan-Young Ock, Tae Min Kim, Jin Ho Kim, Eun-Jae Chung, Seong Keun Kwon, Soon-Hyun Ahn, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo
Korean J Intern Med. 2021;36(1):175-181. Published online March 30, 2020
Background/Aims: Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor characterized by indolence, with a high rate of local recurrence and distant metastasis. This study aimed to investigate the effect of concurrent chemoradiation (CCRT) on locally advanced unresectable ACC.
Methods: We re..
|
|
|
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
Shin Hye Yoo, Chan-Young Ock, Bhumsuk Keam, Sung Joon Park, Tae Min Kim, Jin Ho Kim, Yoon Kyung Jeon, Eun-Jae Chung, Seong Keun Kwon, J. Hun Hah, Tack-Kyun Kwon, Kyeong Chun Jung, Dong-Wan Kim, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo
Korean J Intern Med. 2019;34(6):1313-1323. Published online November 16, 2018
Background/Aims: Since patients with human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) have favorable outcomes after treatment, treatment de-escalation for these patients is being actively investigated. However, not all HPV-positive HNSCCs are curable, and some pati..
|
|
|
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2019;34(5):1116-1124. Published online June 29, 2018
Background/Aims: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factor..
|
|
|
Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
Koung Jin Suh, Ki Hwan Kim, Ryul Kim, Ja Min Byun, Miso Kim, Jin Hyun Park, Bhumsuk Keam, Tae Min Kim, Jin-Soo Kim, In Sil Choi, Dae Seog Heo
Korean J Intern Med. 2019;34(4):894-901. Published online February 23, 2018
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear.
Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118..
|
|
|
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med. 2019;34(4):885-893. Published online November 20, 2017
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
Methods..
|
|
|
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|
|
|
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small
cell lung cancer with activating epidermal growth factor receptor mutations
Sehhoon Park, Seongyeol Park, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
Korean J Intern Med. 2016;31(6):1140-1149. Published online March 28, 2016
Background/Aims: Pretreatment nutritional status is an important prognostic factor in patients treated with conventional cytotoxic chemotherapy. In the era of target therapies, its value is overlooked and has not been investigated. The aim of our study is to evaluate the value of nutritional status ..
|
|
|
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation
Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Dong-Young Kim, Chae-Seo Rhee, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo
Korean J Intern Med. 2016;31(3):570-578. Published online March 15, 2016
Background/Aims: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We ev..
|
|
|
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Kyoung Min Cho, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2015;30(6):891-898. Published online October 30, 2015
Background/Aims: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure.
Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National Uni..
|
|
|
Nephrology
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
Seon Ha Baek, Hyunsuk Kim, Jeonghwan Lee, Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Jin Suk Han, Tae Min Kim, Se-Hoon Lee, Kwon-Wook Joo
Korean J Intern Med. 2014;29(1):40-48. Published online January 2, 2014
Background/Aims: Sunitinib is an oral multitargeted tyrosine kinase inhibitor
used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse
effects (RAEs) of sunitinib have not been investigated. The aim of this study
was to determine the incidence and risk factors of RAEs (..
|
|
|
